Nature Reviews Drug Discovery contents September 2014 Volume 13 Number 9 pp 639-709

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
September 2014 Volume 13 Number 9		Advertisement
Impact Factor 37.231 *	In this issue Comment News and Analysis Research Highlights Reviews Also this month  Featured article: Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders Katrina J. Falkenberg & Ricky W. Johnstone	Human iPSC-derived Cells: Download Free Application Protocols! Explore our library of protocols covering various end-points for cellular research, drug discovery & more Backed by industry-leading technical support Access CDI's suite of iCell® protocols today!
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
nature.com webcasts Macmillan Science Communication presents a custom webcast on: Accelerating therapeutic development through PET and optical preclinical imaging Thursday September 4, 2014 9AM PDT, 12PM EDT, 5PM BST/ 6PM CEST  Register for the webcast and live Q and A session Sponsored by: www.perkinelmer.com
Comment: Getting real in clinical trials John Parkinson p639 | doi:10.1038/nrd4415 How can real-world data from electronic health records be harnessed to improve the effectiveness and efficiency of clinical trials? Full Text | PDF
NEWS AND ANALYSIS		Top
Massive schizophrenia genomics study offers new drug directions Elie Dolgin p641 | doi:10.1038/nrd4411 But much more basic research on disease pathways is needed to entice more pharmaceutical companies back to the field. PDF
Bank tests drug development waters Asher Mullard p643 | doi:10.1038/nrd4412 The European Investment Bank has invested €75 million in a risk-sharing drug development deal with the pharmaceutical company UCB, potentially opening up a new source of research and development (R&D) funding. PDF
NEWS IN BRIEF Ebola outbreak triggers new development programmes p644 | doi:10.1038/nrd4424 PDF
FDA approves first PI3K inhibitor p644 | doi:10.1038/nrd4425 PDF
FDA approves second transgenic milk drug p645 | doi:10.1038/nrd4426 PDF
BIOBUSINESS BRIEFS Trial watch: Atopic dermatitis therapy breakthrough on the horizon? Megan Cully p645 | doi:10.1038/nrd4414 PDF
Market watch: A framework for biomedical innovation in emerging markets Ajay Gautam & Steve Yang p646 | doi:10.1038/nrd4413 PDF
PATENT WATCH Stelara safe after IL-12 antibody dispute Charlotte Harrison p647 | doi:10.1038/nrd4423 PDF
AN AUDIENCE WITH Bob More p648 | doi:10.1038/nrd4421 Bob More, venture capitalist with the Bill and Melinda Gates Foundation, discusses the challenges of aligning financial and philanthropic interests. PDF
FROM THE ANALYST'S COUCH The HIV pipeline Angel Wong p649 | doi:10.1038/nrd4364 The developmental pipeline of HIV antiretroviral therapies is large and diverse, spanning a number of different drug classes. This article provides an overview of the agents in development, including combination therapies, and an analysis of the market for current and future HIV treatments. PDF
RESEARCH HIGHLIGHTS Top Neurodegenerative diseases: Pillars of remyelination p651 | doi:10.1038/nrd4416 PDF Epilepsy: Endocannabinoid metabolism offers handle to dampen down excitability p652 | doi:10.1038/nrd4418 PDF Obesity and diabetes: FGF1 goes long to tackle diabetes p652 | doi:10.1038/nrd4419 PDF Neurodevelopmental disorders: Righting Rett syndrome with IGF1 p653 | doi:10.1038/nrd4417 PDF Anticancer drugs: Using CTCs to test drug sensitivity p654 | doi:10.1038/nrd4420 PDF IN BRIEF Antivirals: Engineered T cells as broad-spectrum antivirals | Cancer: Epigenetic target in Hedgehog-driven tumours | Malaria: Complete protection with AMA1-RON2 complex? | Cancer: PLK4 inhibitor shows potent antitumour activity PDF Drug Discovery JOBS of the week Post-Doc position in electro-spinning -- scaffolding and drug delivery for regenerative medicine applications Center for Nanomedicine and Tissue Engineering - A.O. Niguarda Ca' Granda Postdoctoral Fellow - Statistician / Bioinformatician - Proteomics European Molecular Biology Laboratory (EMBL) Postdoctoral Fellow Cleveland Clinic Post-Doctoral Fellowship The Translational Genomics Research Institute (TGen) More Science jobs from Drug Discovery EVENT HIV Drug Therapy in the Americas 2015 16.04.15 Mexico City, Mexico More science events from
Advertisement
Tumor Xenograft Data Available for Oncology Animal Models Selecting the most appropriate immunodeficient model for a xenograft study is one of the more challenging steps an oncology researcher faces. To help you select the right model, Charles River has compiled xenograft study data that enables you to easily review tumor growth by cell line and tissue type in several of our key animal models. Download a Copy Today>>
REVIEWS		Top
Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies Samir Mitragotri, Paul A. Burke & Robert Langer p655 | doi:10.1038/nrd4363 Biological drugs offer high specificity and potency, but their formulation and delivery pose substantial challenges. Here, the authors highlight recent advances in formulation strategies, describe current and emerging delivery routes and review the potential of targeted and intracellular delivery of biologics. Abstract | Full Text | PDF | Supplementary information
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders Katrina J. Falkenberg & Ricky W. Johnstone p673 | doi:10.1038/nrd4360 Histone deacetylases (HDACs) are a class of epigenetic enzymes that remove acetyl groups from lysine residues on histones and other proteins. In this Review, the authors highlight the role of HDACs in cancer, neurological diseases and immune disorders, and discuss the development of small-molecule inhibitors. Abstract | Full Text | PDF | Supplementary information
Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders P. Jeffrey Conn, Craig W. Lindsley, Jens Meiler & Colleen M. Niswender p692 | doi:10.1038/nrd4308 G protein-coupled receptors (GPCRs) are highly successful drug targets, particularly for central nervous system (CNS) disorders. Compared to traditional drugs that target the orthosteric ligand-binding site of GPCRs, allosteric modulators have the potential to achieve greater subtype selectivity and allow the normal function of endogenous ligands to be preserved. Conn and colleagues reflect on the key principles for successful optimization of GPCR allosteric modulators. Abstract | Full Text | PDF | Supplementary information
Advertisement
Immuno-Oncology Takes Center Stage at The International Symposium for Tissue Phenomics™ Hear cancer experts present how they are finding new markers for stratifying populations, as well as how immuno-oncology is accelerating using quantitative spatial analysis of the tumor microenvironment. Register today to join us October 17-18 in San Francisco.
Erratum: Harnessing the informatics revolution for neuroscience drug R&D Husseini K. Manji, Thomas R. Insel & Vaibhav A. Narayan p709 | doi:10.1038/nrd4431 Full Text | PDF
Advertisement
nature.com webcasts Macmillan Science Communication presents a custom webcast on: Targeting the untargeted in translational research Thursday September 11, 2014 Session 1: Europe and the Middle East 2PM BST, 3PM CEST, 5PM GST Session 2: USA 9AM PDT, 11AM CDT, 12PM EDT  Register for the webcast and live Q and A session Sponsored by: www.home.agilent.com
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2013 Journal Citation Report (Thomson Reuters, 2014)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.